

1 **Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis:**  
2 **a mathematical modeling analysis**

3  
4 January 24, 2024

5  
6 Lyndon P. James,<sup>1,2</sup> Fayette Klaassen,<sup>3</sup> Sedona Sweeney,<sup>4</sup> Jennifer Furin,<sup>5</sup> Molly F. Franke,<sup>5</sup> Reza  
7 Yaesoubi,<sup>6</sup> Dumitru Chesov,<sup>7,8</sup> Nelly Ciobanu,<sup>9</sup> Alexandru Codreanu,<sup>9</sup> Valeriu Crudu,<sup>9</sup> Ted Cohen,<sup>10</sup>  
8 Nicolas A. Menzies<sup>2,3</sup>

9  
10 **Affiliations:**

- 11 1. PhD Program in Health Policy, Harvard University, Cambridge, MA, USA
- 12 2. Center for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, MA,  
13 USA
- 14 3. Department of Global Health and Population, Harvard T. H. Chan School of Public Health,  
15 Boston, MA, USA
- 16 4. Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London,  
17 UK
- 18 5. Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA
- 19 6. Department of Health Policy and Management, Yale School of Public Health, New Haven, CT,  
20 USA
- 21 7. Discipline of Pneumology and Allergology, Nicolae Testemitanu State University of Medicine  
22 and Pharmacy, Chisinau, Moldova
- 23 8. Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- 24 9. Chiril Draganiuc Institute of Phthisiopneumology, Chisinau, Moldova
- 25 10. Department of Epidemiology and Microbial Diseases, Yale School of Public Health, New Haven,  
26 CT, USA

27  
28 **Corresponding author:** LPJ

29 **Corresponding author email:** [lyj519@mail.harvard.edu](mailto:lyj519@mail.harvard.edu)

30  
31 **ABSTRACT**

32  
33 **Background:** Emerging evidence suggests that shortened, simplified treatment regimens for rifampicin-  
34 resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment outcomes to longer regimens.

35 We compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxacin  
36 (BPaLM) to a standard of care strategy using a 9- or 18-month regimen depending on whether  
37 fluoroquinolone resistance (FQ-R) is detected on Drug Susceptibility Testing (DST).

38  
39 **Methods and Findings:** The primary objective was to determine whether 6 months of BPaLM is a cost-  
40 effective treatment strategy for RR-TB. We used genomic and demographic data to parameterize a  
41 mathematical model estimating long-term health outcomes measured in quality-adjusted life years  
42 (QALYs) and lifetime costs in 2022 USD (\$) for each treatment strategy for patients 15 years and older

43 diagnosed with pulmonary RR-TB in Moldova, a country with a high burden of TB drug resistance. For  
44 each individual, we simulated the natural history of TB and associated treatment outcomes, as well as the  
45 process of acquiring resistance to each of 12 anti-TB drugs. Compared to the standard of care, 6 months  
46 of BPaLM was cost-effective. It was estimated to reduce lifetime costs by \$3,366 (95% UI: [1465, 5742]  
47  $p < 0.001$ ) per individual, with a non-significant change in QALYs (-0.06; 95% UI: [-0.49, 0.032]  
48  $p = 0.790$ ). For those stopping moxifloxacin under the BPaLM regimen, continuing with BPaL plus  
49 clofazimine (BPaLC) provided more QALYs at lower cost than continuing with BPaL alone. 6 months of  
50 BPaLM had at least a 93% chance of being cost-effective, so long as BPaLC was continued in the event  
51 of stopping moxifloxacin. 6 months of BPaLM reduced the average time spent with TB resistant to  
52 amikacin, bedaquiline, clofazimine, cycloserine, moxifloxacin and pyrazinamide, while it increased the  
53 average time spent with TB resistant to delamanid and pretomanid. Sensitivity analyses showed 6 months  
54 of BPaLM to be cost-effective across a broad range of values for the relative effectiveness of BPaLM, and  
55 the proportion of the cohort with FQ-R. Compared to the standard of care, 6 months of BPaLM would be  
56 expected to save Moldova's national TB program budget \$7.1 million (95% UI: [1.3 million, 15.4  
57 million]  $p = 0.002$ ) over the five year period from implementation. This analysis did not account for all  
58 possible interactions between specific drugs as they apply to treatment effectiveness, to resistance  
59 acquisition, or to the consequences of specific types of severe adverse events, nor did it model how the  
60 intervention may affect the transmission dynamics of RR-TB.

61  
62 **Conclusions:** Compared to the standard of care, the implementation of the 6-month BPaLM regimen  
63 could improve the cost-effectiveness of care for individuals diagnosed with RR-TB, particularly in  
64 settings where current long-course regimens are challenging to implement and afford. Further research  
65 may be warranted to explore the suitability of shorter RR-TB regimens in specific national settings.

## 66 **AUTHOR SUMMARY**

67

### 68 **Why was this study done?**

- 69
- Drug resistance poses a major barrier to the effective treatment of tuberculosis, especially in  
70 Moldova and other post-Soviet states which have the highest levels of resistance in the world.

71

  - Individuals with tuberculosis resistant to the key drug rifampicin face a worse prognosis, a longer  
72 and more expensive course of treatment, and more side effects than individuals with rifampicin-  
73 susceptible tuberculosis.

74

  - Until recently, the standard of care for rifampicin-resistant tuberculosis involved many drugs in  
75 combination, often given for 18 months or longer.

76

  - The newer, 6-month “BPaLM” regimen is comprised of four drugs (bedaquiline, pretomanid,  
77 linezolid, moxifloxacin) to which resistance levels are currently low, and while it was shown to  
78 be just as effective as the standard of care for 72-week health outcomes, its effect on lifetime  
79 health outcomes, costs, and the acquisition of drug resistance was less clear.

80

81

82

83

### 84 **What did the researchers do and find?**

- Using a mathematical model, we projected the lifetime health benefits and costs of the 6-month  
85 BPaLM regimen as compared to the standard of care treatments for rifampicin-resistant  
86 tuberculosis, and found that 6 months of BPaLM provided similar health benefits to longer  
87 regimens, at lower cost.
- 88

89

- 90       • Compared to the standard of care, we also found that the 6-month BPaLM regimen shortened the  
91       average duration of tuberculosis that was resistant to the drugs amikacin, bedaquiline,  
92       clofazimine, cycloserine, moxifloxacin, and pyrazinamide, while it increased the average duration  
93       of tuberculosis resistant to delamanid and pretomanid.
- 94
- 95       • For individuals receiving BPaLM who had to stop taking the drug moxifloxacin, we found that it  
96       would be beneficial on both health and cost grounds to replace it with clofazimine, thereby  
97       topping the regimen back up to four drugs.

98

99   **What do these findings mean?**

- 100       • Using conventional benchmarks for value-for-money, 6 months of BPaLM is a cost-effective  
101       approach for the treatment of rifampicin-resistant tuberculosis in Moldova, and potentially other  
102       post-Soviet countries.
- 103
- 104       • Though the effect of the 6-month BPaLM regimen on the spread of drug resistance in the  
105       population is uncertain and not addressed directly by this study, this combination of newer drugs  
106       appears to achieve cure more quickly, which reduces the amount of time an individual is  
107       potentially infectious and so may be beneficial in fighting resistance to several drugs, even while  
108       it may increase the spread of resistance to others.
- 109
- 110       • Further studies may be warranted to explore how well these findings translate to different global  
111       regions where health system capabilities, costs, and existing resistance patterns may differ.

112

## 1 INTRODUCTION

2 Treatment for rifampicin-resistant tuberculosis (RR-TB) is complex, involving combinations of several  
3 drugs—many of which have substantial potential for toxicity—over a prolonged course of therapy. The  
4 2022 WHO Guidelines for the treatment of drug-resistant tuberculosis recommend a shorter, 6-month  
5 regimen composed of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) to treat rifampicin-  
6 resistant tuberculosis (RR-TB) [1]. These guidelines updated earlier 2020 WHO Guidelines that  
7 recommended several treatment regimens, each comprising 4-7 drugs for 9-18 months or longer [2].

8  
9 The evidence base for shorter regimens for RR-TB has been broadly positive, including results from  
10 observational studies [3,4], single-arm clinical trials [5,6], mathematical modeling analyses [7], and the  
11 recent multicenter open-label randomized controlled trial TB-PRACTECAL [8]. Although trial  
12 recruitment was stopped early on the recommendation of a planned, interim review by the study  
13 monitoring committee, the analysis suggested that 6 months of BPaLM was non-inferior to the standard  
14 of care with respect to treatment outcome (a composite of death, treatment failure, treatment  
15 discontinuation, loss to follow-up, or recurrence) and was beneficial with respect to safety [8]. The  
16 adoption of shorter, simplified regimens may be further bolstered by the forthcoming publication of the  
17 results of the endTB trial [9–13], but the absence of larger, confirmatory trials led to a conditional  
18 recommendation by the WHO in 2022. The pursuit of effective shorter treatment regimens is also driven  
19 by the desire to alleviate the considerable psychological and emotional toll of prolonged treatment for  
20 RR-TB. On top of drug side effects [14], many patients undergoing treatment for RR-TB experience  
21 stigma, depression, loss of self-esteem, and economic hardship from an inability to work [15]. Patients  
22 may lack access to sufficient psychological and financial supports [16–18], and this may be particularly  
23 hard for individuals with housing or employment instability, or substance use disorder [19].

24

25 The 2020 WHO Guidelines represent the existing standard of care in many settings. In addition to higher  
26 prices and supply constraints for newer drugs [20][21], it is expected that the rollout of the BPaLM  
27 regimen as part of the newer 2022 Guidelines may be delayed by concerns about comparative  
28 effectiveness and cost-effectiveness [20–24]. Implementation may also be met with concern over the  
29 emergence of drug resistance, particularly in settings with limited capacity to detect resistance to newer  
30 agents such as bedaquiline, pretomanid, and linezolid [25]; such capacity constraints are multifactorial,  
31 from the expense of investing in new technologies and associated laboratory workforce development, to  
32 supply chain interruptions and divergent political priorities [26,27]. The decision to implement the new 6-  
33 month BPaLM regimen will depend on setting-specific tradeoffs between regimen effectiveness, cost, the  
34 complexity of treatment decisions, and existing levels of resistance to anti-TB drugs in the population.  
35 Decision analysis provides a framework to analyze these tradeoffs, and a recent cost-effectiveness study  
36 using evidence from TB-PRACTECAL found that 6-months BPaLM may reduce cost and improve health  
37 relative to the standard of care in several countries [28]. Our analysis builds on this work by focusing on  
38 longer term outcomes that are difficult to measure in a trial setting and by examining a wider range of  
39 testing and treatment approaches, including whether patients who must stop moxifloxacin—due to side  
40 effects or acquired resistance—should continue on BPaL alone, or BPaL plus clofazimine (BPaLC)  
41 [25,28].

42  
43 In this study, we investigated the health impact and cost-effectiveness a 6-month BPaLM regimen for the  
44 treatment of adults with pulmonary RR-TB, as compared to the standard of care. We considered a range  
45 of treatment strategies incorporating these two approaches, varying the timing and frequency of drug  
46 susceptibility testing (DST) as well as how regimens would be modified for individuals developing  
47 fluoroquinolone resistance. To estimate outcomes, we used a Markov microsimulation model  
48 parameterized with detailed genomic sequencing data describing specific patterns of initial drug  
49 resistance, and calculated the effect of each treatment strategy on length and quality of life as well as

50 costs, accounting for regimen effectiveness, risks of severe adverse events (SAEs) due to drug toxicity,  
51 and acquisition of resistance.

52  
53 We conducted the analysis for the setting of Moldova, an upper-middle income post-Soviet country where  
54 the incidence rate of RR-TB is among the highest in the world, and where an estimated 33% of  
55 individuals newly diagnosed with TB have RR-TB, ten times higher than the same proportion globally  
56 [29,30]. The reasons for this picture are not fully understood, but it is thought that economic shocks  
57 following the breakup of the Soviet Union contributed to this picture in the region, along with early  
58 treatment discontinuation [31] and mass incarceration [32]. In recent years in Moldova, a  
59 multidisciplinary committee reviews the treatment course of every patient receiving treatment for RR-TB,  
60 and WHO treatment guidelines are closely adhered to [VC, DC]. Moldova also has developed a robust TB  
61 laboratory infrastructure, which provided a platform for recent genomic sequencing of culture-positive  
62 isolates [33]. By harnessing this genomic resistance data, we hope to improve the cost-effectiveness of  
63 treatment in a country with a very high burden of RR-TB, as well as other countries in the region. We also  
64 explored the generalizability of our findings to settings with a different prevalence of initial  
65 fluoroquinolone resistance among RR-TB.

## 1   **METHODS**

### 2   **Strategies**

3   We compared eight treatment strategies, each reflecting a different approach to drug regimen choice and  
4   timing of DST (Table 1). Two strategies adopted drug regimens aligned with the standard of care as  
5   defined by the 2020 WHO Guidelines [2], with all individuals started on a WHO longer regimen while  
6   awaiting the results of second-line DST by mycobacterial growth indicator tube (MGIT) to  
7   fluoroquinolones and injectables. Fluoroquinolone resistance (FQ-R) identified via MGIT was assumed to  
8   result in the continuation of an 18-month WHO longer regimen, with refinements as necessary based on  
9   DST. If fluoroquinolone susceptibility (FQ-S) was detected, treatment was switched to a 9-month  
10   regimen (S1 Fig). Under one standard of care strategy (strategy (7)), we modelled the minimum  
11   guideline-recommended frequency of second-line DST—every 4 months, and in another (strategy (8)) we  
12   increased this to a monthly frequency. While the 2020 WHO Guidelines did not prescribe exactly one  
13   combination of drugs for each scenario, we adopted a single combination of drugs for each situation for  
14   tractability, based on our best interpretation of the guideline’s hierarchy of group A, B, and C drugs (S1  
15   Fig).

16   The remaining six strategies were modeled on the 2022 WHO Guidelines [34] with 6-month BPaLM-  
17   based regimens. In three of these strategies, individuals having to stop Moxifloxacin (because of a SAE or  
18   because resistance was detected on DST) were continued on BPaL alone, as recommended by the 2022  
19   Guidelines. In the remaining three, they continued on BPaLC. The remaining differences between these  
20   six strategies depended on the prescribed schedule of DST to second-line drugs; in two of these strategies,  
21   we explored the effects of omitting routine second-line DST at treatment initiation (Table 1).



1 **Table 1. Key features of the modeled RR-TB treatment strategies.**

2

Strategy No.	Guidelines informing the strategy	Drug regimen	Regimen duration	For BPaLM-based strategies only, prescribed regimen for those who discontinue Moxifloxacin	Replacement drugs, in order, for all other discontinuations	DST for second-line drugs (MGIT) at treatment initiation	Routine frequency of subsequent DST for second-line drugs	Indications for drug discontinuation	Length of regimen extension, if necessary*	
1	2022 WHO Guidelines	BPaLM	6 months	BPaLC	Clofazimine, Cycloserine	Yes	4 months	Immediately following: • Resistance identified on DST • Grade 4-5 Severe Adverse Event	6 months	
2	2022 WHO Guidelines	BPaLM	6 months	BPaLC		Yes	1 month			
3	2022 WHO Guidelines	BPaLM	6 months	BPaL		Yes	4 months			
4	2022 WHO Guidelines	BPaLM	6 months	BPaL		Yes	1 month			
5	2022 WHO Guidelines	BPaLM	6 months	BPaLC		No	4 months			
6	2022 WHO Guidelines	BPaLM	6 months	BPaL		No	4 months			
7	2020 WHO Guidelines (standard of care)	Start treatment with WHO Longer regimen (bedaquiline, clofazimine, linezolid, moxifloxacin), await second-line DST.  <b>If FQ-R</b> , continue on WHO Longer regimen, i.e.: Bedaquiline, Clofazimine, Linezolid, Cycloserine			Ethambutol, Delamanid, Pyrazinamide, Amikacin, Ethionamide	Yes	4 months			
		<b>If FQ-S</b> , switch to 2020 WHO shorter, all-oral bedaquiline containing regimen: Bedaquiline, Clofazimine, Ethambutol, Ethionamide, Isoniazid, Moxifloxacin, Pyrazinamide			Delamanid, Cycloserine					
8	2020 WHO Guidelines (standard of care)	As for Strategy No. 7					Yes	1 month		

3

4 BPaL – bedaquiline, pretomanid, linezolid; BPaLC – bedaquiline, pretomanid, linezolid, clofazimine; BPaLM – bedaquiline, pretomanid,

5 linezolid, moxifloxacin; DST – drug susceptibility test; FQ-S – fluoroquinolone susceptible; FQ-R – fluoroquinolone resistant; MGIT –

6 mycobacterial growth indicator tube; WHO – World Health Organization

7 \*Regimen extensions were implemented for those who had not yet successfully completed treatment. While the 2020 WHO Guidelines  
8 recommended the BPAL regimen in specific situations, none of the modeled cohort met the inclusion criteria to receive BPAL under those  
9 strategies.

## 1 **Population and data**

2 We modeled a cohort of individuals aged 15 years and older diagnosed with RR-TB in Moldova. For each  
3 individual, their age and the resistance profile of the strain of *M. tuberculosis* causing infection were  
4 informed by publicly available genomic sequencing data from Moldova [35]. These data comprised  
5 single-strain *M. tuberculosis* samples collected in 2018–2019; a full description has been provided by  
6 Yang and colleagues [30]. We assumed that a mutation associated with resistance conferred full  
7 resistance to that drug. Conversely, *M. tuberculosis* strains lacking relevant resistance mutations were  
8 assumed to be fully susceptible to the respective drugs. We excluded data for rifampicin susceptible  
9 strains (S2 Fig) leaving 674 distinct samples from which we simulated the modeled population. The  
10 proportion of isolates with resistance to each drug is shown in S3 Fig. This analysis used publicly  
11 available data only, and did not require ethical approval.

12

## 13 **Model**

14 We used a Markov microsimulation model to simulate lifetime outcomes for a cohort of 10,000  
15 individuals. Individuals in the model were simulated by random draws from the genomic sequencing  
16 dataset, with replacement. They were each assigned a drug regimen based on the modeled strategy (Table  
17 1). Individuals then were assumed to transition between four health states: (1) Receiving TB treatment,  
18 (2) TB disease – not receiving treatment, (3) Cured post-treatment, and (4) Dead (S4 Fig). Within each  
19 Markov state, individual events were tracked including true cure as a result of treatment or self-cure, the  
20 occurrence of SAEs, second-line DST, changes to the drug regimen, loss to follow-up, relapse, death, and  
21 the evolution of drug resistance for that individual's strain of *M. tuberculosis*. Extensions to the treatment  
22 regimen were implemented for those not observed to have successfully completed treatment.

23 While the range of SAEs resulting from TB treatment are of many varying durations and degrees of  
24 impact on quality of life, we accounted for these events in a simplified way by modeling the risk of a

25 grade 4-5 SAE during the first three months of exposure to each drug, with each grade 4-5 SAE  
26 conferring a small but lifelong deduction in quality of life (Table 2, S1 Table). Grade 4-5 SAEs and  
27 diagnosed resistance constituted lifetime contraindications to the relevant drug, and replacements were  
28 made according to the modeled strategy (Table 1).

1 **Table 2. Key model parameters.**

Parameter	Point Estimate	Distribution	Source(s)	Notes
Rate of death from untreated TB, annual	0.389	Published point estimate (median) and 95% CrI (0.335-0.449) modeled as Lognormal (mu -0.9442, sigma 0.0763)	Ragonnet R, et al. Clin Infect Dis 2020 [36]	Applied to those with TB who are no longer receiving treatment (i.e., those LTFU and those who appeared to successfully complete treatment but had not been truly cured).
Mortality rate ratio for those who are cured, compared to background mortality	3.070	Published point estimate and 95% CI (2.12, 4.45) modeled as Lognormal (mu 1.122, sigma 0.1889)	Romanowski K., et al. Lancet Infect Dis 2019 [37]	Estimate for pulmonary TB.
Rate of self-cure, annual	0.231	Published point estimate and 95% CrI (0.177, 0.288) modeled as Lognormal (mu -1.465, sigma 0.136)	Ragonnet R, et al. Clin Infect Dis 2020 [36]	Applied to those no longer receiving treatment (i.e., those LTFU and those who appeared to successfully complete treatment but had not been truly cured) and the first two months of treatment.
Probability of all-cause death for WHO longer regimen, MDR only (excluding XDR), at 21 months	0.080	N/A	Bastos M. L., et al. 2017 [38]	To convert to a monthly estimate for disease-specific mortality, we assumed a 21 month regimen duration. Further detail in S2 Appendix.

Parameter	Point Estimate	Distribution	Source(s)	Notes
Mortality rate among those who are not cured but on treatment, MDR-TB only (excluding XDR-TB), monthly	0.00536	Beta (mean 0.00536, s.d. 0.00178)*	Bastos M. L., et al. 2017 [38]	See S2 Appendix.
Probability of observed success for a fully effective WHO longer regimen, MDR-TB only (excluding XDR), at 21 months	0.640	Published point estimate and 95% CI (0.63-0.65) modeled as Beta (mean 0.64, s.d. 0.0051)	Bastos M. L., et al. 2017 [38]	To convert to a monthly cure rate for Standard of Care strategies, we assumed a 21 month regimen duration. We used this parameter specifically to inform the effectiveness of a <i>fully effective</i> regimen of 4 drugs (i.e., a regimen composed of 4 drugs to which the individual's strain of <i>M.tb.</i> is truly susceptible). See also S2 Appendix.
Hazard Rate Ratio of cure for each effective drug in the regimen (relative to one fewer effective drugs)	1.65	Published point estimate and 95% CI (1.48, 1.84) modeled as Lognormal (mu 0.5008, sigma 0.056)	Yuen, CM. et al. PLoS Med 2015 [39]	Applied to a maximum of 4 drugs (i.e., there is no further increase in the monthly cure rate for 5 drugs compared to 4).
Hazard Rate Ratio of cure for the BPALM regimen as compared to the SOC	1.59	Published point estimate and 95% CI (1.18, 2.14) modeled as Lognormal (mu 0.453, sigma 0.147)	Nyang'wa, B.-T. et al. 2022 [8]	The referenced estimate is based on the outcome of time to sputum culture conversion. We assume the same relationship holds for the rate of true cure, and explore this assumption in sensitivity analysis.

Parameter	Point Estimate	Distribution	Source(s)	Notes
Probability of acquiring resistance to a drug, conditional on treatment with a regimen of 4 or more effective drugs, over 6 months	0.008	Published point estimate and 95% CI (0.005, 0.01) modeled as Beta (mean 0.008, s.d. 0.0015)	Lew W. et al. Annals Intern Med 2008 [40]	We define an “effective” drug as one to which the strain of <i>M. tuberculosis</i> is susceptible. We use the published estimate to produce a monthly rate of resistance acquisition, which is constant conditional on the number of effective drugs.

- 2 BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin, CI – confidence interval; CrI – credibility interval; LTFU – lost to follow up; M. tb. –
- 3 mycobacterium tuberculosis; MDR – multidrug-resistant; NHB – Net Health Benefit; QALY – Quality-adjusted Life Year; RR-TB – rifampicin-
- 4 resistant tuberculosis; TB – tuberculosis; UI – Uncertainty Interval; USD – United States Dollars; WHO – World Health Organization; WTP –
- 5 Willingness-to-Pay; XDR – extensively drug resistant.
- 6 Please see S1 Table for the full set of model parameter descriptions, and S2 Table for the probabilities of loss to follow up by month of treatment.

1 Each month, we tracked the drug regimen and the true resistance profile of each individual's strain of *M.*  
2 *tuberculosis*. The number of effective drugs in a regimen was defined as the sum of all drugs being  
3 received, minus those drugs to which the strain of *M. tuberculosis* was resistant. The effect estimate for  
4 cure in BPaLM-based strategies as compared to the standard of care was modeled as the trial estimate for  
5 sputum culture conversion from TB-PRACTECAL, conditional on the number of effective drugs in the  
6 regimen, up to a maximum of four (i.e., four effective drugs confer a higher monthly cure rate than three,  
7 but five or more effective drugs do not confer a higher monthly cure rate than four) [8]. We varied this  
8 parameter in sensitivity analysis. S3 Fig displays the modeled rate of acquisition of new resistance to each  
9 drug, which was also conditioned on the number of effective drugs, to a maximum of four. S1 Table  
10 details the derivation and values for these and all other model parameters. DST was performed at a  
11 frequency informed by the strategy (Table 1), with sensitivity and specificity incorporated for each (S1  
12 Table). Additional detail on model structure is provided in the S1 Appendix.

13

## 14 **Outcomes**

15 The primary health outcome was measured in quality-adjusted life years (QALYs), a conventional  
16 approach in cost-effectiveness analysis [41,42]. QALYs measure the total length of time lived, weighted  
17 by time-varying, health-related quality of life, where 1 QALY is valued equivalently to one year in a state  
18 of perfect health [42,43]. This approach integrates the effects of the treatment strategies on both length  
19 and quality of life. QALYs rely on several assumptions, including risk-neutrality over length of life, and  
20 that maximizing total population QALYs—summed across all individuals—is desirable [44]. For each  
21 modeled individual in each month, we assigned health-related quality of life weights on a scale from 0  
22 (dead) to 1 (perfect health), and multiplied the weight by 1/12 to account for the one-month cycle length  
23 (i.e., a dead individual accrued 0 QALYs for that month, and an individual in perfect health accrued 1/12  
24 QALYs). These estimates were lowest on average at presentation and increased during the course of  
25 treatment; grade 4-5 SAEs also conferred a decrement in the utility weight (S1 Table). The total QALYs



26 were calculating by summing all the month-specific QALYs accrued over each modeled individual's  
27 lifetime.

28 We measured the impact on drug resistance by summing for each individual, and for each of 12 anti-TB  
29 drugs, the number of months they experienced TB disease with resistance to that drug. We then calculated  
30 three summary measures for the impact on drug resistance. In the first, we calculated the mean duration  
31 with resistance to each drug for the entire cohort by aggregating the time with resistance across the whole  
32 cohort for each drug, then dividing by the size of the starting cohort. Second, we calculated the mean  
33 duration of *untreated* TB disease with resistance to each drug by summing the time with resistance only  
34 among those individuals in Markov state (2)—TB disease no longer receiving treatment—and again  
35 averaging across the starting cohort. These measures were designed to reflect the relevance of the policies  
36 for the transmission of drug resistance . We calculated both because—for individuals no longer receiving  
37 treatment—there could be a higher risk that *M. tuberculosis* will transmit to another host, compared to the  
38 cohort as a whole. Third, we calculated the lifetime cumulative incidence of acquiring resistance to each  
39 drug, per individual in the cohort.

40 As a set of secondary health outcomes, we calculated the number of grade 4-5 SAEs experienced per  
41 patient to each of the drugs, and total life years (LYs, i.e. not weighted by health-related quality of life).  
42 To permit the validation of our model results, we also tracked two types of shorter-term outcomes at 6  
43 months, 12 months, and 17 months (i.e., 72 weeks, the trial endpoint in TB-PRACTECAL): a) the  
44 proportion of individuals experiencing the end-of-treatment outcomes of Success, Failed by Treatment,  
45 Lost to Follow-up (LTFU), and Dead, as would typically be reported programmatically to the WHO; and  
46 b) a composite unfavorable outcome, including Death, LTFU, failed by treatment, and grade 4-5 SAEs,  
47 based on the primary outcome in TB-PRACTECAL [8].

48 We measured the total costs under each strategy from a societal perspective in 2022 United States dollars  
49 (\$) as the sum of direct medical, direct non-medical, and indirect costs accruing in each period. Direct  
50 medical costs (i.e., those arising directly from the consumption of healthcare goods and services) were

51 calculated by adding the costs of the drugs received, laboratory culture and DST to second-line drugs, a  
52 baseline healthcare resource utilization in the form of inpatient and outpatient services, and the cost of  
53 LTFU tracing. Direct non-medical and indirect costs were informed by published estimates for Moldova  
54 [45]. Each grade 4-5 SAE was accompanied by a utilization cost for inpatient and outpatient services.  
55 Direct non-medical costs (e.g., transportation) and indirect costs (e.g., productivity losses) accrued for  
56 every additional month on treatment. The indirect costs also accrued for those LTFU prior to cure.  
57 Productivity losses secondary to early mortality were not included in total costs, and were calculated  
58 separately.

59 Undiscounted values were calculated for all outcomes. For QALYs and total costs only, discounted values  
60 were also calculated using an annual discount rate of 3%.

#### 61 *Cost-effectiveness analysis*

62 First, we ruled out dominated strategies (i.e., those strategies that were both more expensive and provided  
63 fewer QALYs on average than a linear combination of other strategies. We then calculated the relevant  
64 incremental cost-effectiveness ratios (ICER; a measure of the additional cost required to produce one  
65 additional QALY, as compared to the next cheapest, non-dominated strategy). We identified the cost-  
66 effective strategy as that with the greatest health gains, subject to the constraint that—in order to provide  
67 value for money—the ICER must be below the willingness-to-pay (WTP) threshold [41,46]. Lower  
68 (\$4700 per QALY) and higher (\$7021 per QALY) benchmarks for these thresholds in Moldova were  
69 based on published estimates using an opportunity cost approach [47], updated to 2022 USD (S1 Table).  
70 As ICERs may be challenging to interpret in some cases [48], we also calculated the Net Health Benefit  
71 (NHB) of each strategy (see S1 Appendix), with the cost-effective strategy identified as that with the  
72 highest NHB [41]. This is mathematically equivalent to the ICER approach. The CHEERS checklist is  
73 included in S1 Checklist [49].

#### 74 *Budget Impact*

75 In order to account for the effect of implementing 6-months of BPaLM on the national TB program  
76 budget in Moldova, we tracked the subset of aforementioned cost outcomes borne by the TB program. We  
77 organized these costs under the following categories: drugs, laboratory tests, routine inpatient and  
78 outpatient care, and non-routine inpatient and outpatient care (i.e., care stemming from the treatment of  
79 grade 4-5 SAEs, for adjustment of a regimen following the detection of resistance on DST, or for LTFU  
80 tracing). The estimated budget impact was calculated for each year over a five year period, scaled to the  
81 annual number of case notifications of RR-TB in Moldova.

## 82 **Statistical analysis**

83 We estimated results via individual-level microsimulation, with lifetime outcomes for each of 10,000  
84 individuals simulated for each of the diagnostic and treatment strategies described above.

### 85 *Sensitivity analyses*

86 Probabilistic Sensitivity Analysis (PSA) was conducted to account for uncertainty by constructing  
87 distributions for model input parameters (S1 Table). In a second-order Monte Carlo simulation, we drew  
88 1,000 parameters sets from the distributions. For each parameter set, the 10,000 individuals were  
89 simulated through each strategy, and a set of results was calculated. Finally, point estimates for each  
90 outcome were calculated as the mean of these 1,000 second-order simulations, and 95% uncertainty  
91 intervals (UIs) were constructed using the 2.5<sup>th</sup> and 97.5<sup>th</sup> centiles [50]. Point estimates and 95% UIs were  
92 also calculated for the differences between leading 6 month BPaLM-based and SOC-based strategies, and  
93 p-values were constructed from the empirical cumulative distribution function of those differences.  
94 Further detail is provided in the S1 Appendix.

95 Some important model parameters have substantial uncertainty. We performed one-way sensitivity  
96 analyses on two of these key inputs to understand the relationship with study outcomes. First, we varied  
97 the main effect estimate for cure across the uniform distribution (1.00, 2.14). Next, we varied the  
98 prevalence of fluoroquinolone resistance among individuals with diagnosed RR-TB across the uniform

99 distribution (0%, 40%) to aid the generalization of results to settings with a different prevalence of  
100 fluoroquinolone resistance.

#### 101 *Validation*

102 We validated the modeled end-of-treatment (EOT) outcomes to estimates reported to WHO over the  
103 period 2010-2019. We also validated the composite of unfavorable outcome at 72 weeks against the  
104 findings of TB-PRACTECAL [8]. Further detail is provided in the S1 Appendix.

#### 105 *Software*

106 The simulation was conducted in TreeAge Pro Healthcare 2023 [51] and figures were made in R [52]  
107 using several packages [53–61]. TreeAge and R code files are available in a repository.[62]

## 1 **RESULTS**

### 2 **Health effects, costs, and cost-effectiveness**

3 Health effects, costs, and cost-effectiveness results for all strategies are presented in Table 3 and Fig 1.

4 Among the 6-month BPaLM strategies, the highest health benefits were achieved by Strategy (1) (BPaLC

5 if Mfx stopped, second-line DST upfront, then repeated at 4 monthly intervals), with undiscounted

6 QALYs of 14.75 (95% UI: [12.76, 16.54]). The two standard of care strategies (Strategies (7) and (8))

7 both produced slightly more QALYs than Strategy (1), with less than 0.01 undiscounted QALYs between

8 them on average. The Life Years (unadjusted for health-related quality of life) obtained under each

9 strategy are displayed in S3 Table.

1 **Table 3. Costs, health impacts, and cost-effectiveness of RR-TB treatment strategies.**

2

Strategy Name	STRATEGY DESCRIPTION			COST		HEALTH IMPACT		COST-EFFECTIVENESS				
	Alternative regimen if Mfx stopped (2022 Guidelines only)	2 <sup>nd</sup> line DST at treatment initiation	Routine frequency of subsequent 2 <sup>nd</sup> line DST	Undiscounted Total Cost (2022 USD)	Discounted Total Cost (2022 USD)	Undiscounted QALYs	Discounted QALYs	Incremental Discounted Total Cost (2022 USD)	Incremental Discounted QALYs	Incremental Cost-effectiveness Ratio	NHB, lower bound WTP (QALYs)	NHB, upper bound WTP (QALYs)
(5) 6 months BPaLM	BPaLC	No	Every 4 months	8,412 (6,469, 10,974)	8,153 (6,279, 10,592)	14.745 (12.72, 16.55)	10.494 (9.26, 11.5)	(comparator)	(comparator)	(comparator)	8.759 (7.42, 9.87)	9.333 (8.07, 10.39)
<b>(1) 6 months BPaLM</b>	<b>BPaLC</b>	<b>Yes</b>	<b>Every 4 months</b>	<b>8,424 (6,469, 10,991)</b>	<b>8,167 (6,299, 10,629)</b>	<b>14.750 (12.76, 16.54)</b>	<b>10.497 (9.28, 11.52)</b>	<b>14 (-170, 205) p=0.876</b>	<b>0.0032 (-0.16, 0.19) p=0.996</b>	<b>4,375</b>	<b>8.759 (7.46, 9.90)</b>	<b>9.334 (8.09, 10.43)</b>
(2) 6 months BPaLM	BPaLC	Yes	Every 1 month	8,663 (6,713, 11,219)	8,398 (6,518, 10,767)	14.753 (12.74, 16.49)	10.500 (9.28, 11.50)	--	--	Dominated*	8.713 (7.40, 9.83)	9.304 (8.05, 10.38)
(6) 6 months BPaLM	BPaL only	No	Every 4 months	9,059 (6,926, 11,876)	8,723 (6,707, 11,394)	14.405 (12.44, 16.10)	10.275 (9.07, 11.24)	--	--	Dominated	8.419 (7.10, 9.51)	9.033 (7.78, 10.07)
(3) 6 months BPaLM	BPaL only	Yes	Every 4 months	9,085 (6,935, 11,925)	8,750 (6,703, 11,436)	14.414 (12.42, 16.17)	10.280 (9.10, 11.29)	--	--	Dominated	8.419 (7.07, 9.55)	9.034 (7.80, 10.09)
(4) 6 months BPaLM	BPaL only	Yes	Every 1 month	9,391 (7,201, 12,126)	9,039 (6,950, 11,635)	14.408 (12.42, 16.16)	10.276 (9.08, 11.28)	--	--	Dominated	8.353 (7.04, 9.50)	8.989 (7.71, 10.08)
(7) Standard of care	N/A	Yes	Every 4 months	11,936 (9,403, 15,102)	11,534 (9,088, 14,619)	14.832 (13.00, 16.54)	10.557 (9.46, 11.54)	3,366 (1,465, 5,742) p=<0.001	0.0600 (-0.32, 0.49) p=0.79	56,100	8.103 (6.88, 9.19)	8.915 (7.77, 9.92)
(8) Standard of care	N/A	Yes	Every 1 month	12,232 (9,727, 15,435)	11,816 (9,395, 14,912)	14.836 (12.98, 16.56)	10.560 (9.46, 11.55)	282 (24, 550) p=0.028	0.0025 (-0.16, 0.18) p=0.996	112,800	8.045 (6.83, 9.10)	8.877 (7.73, 9.87)

3

4 BPaL – bedaquiline, pretomanid, linezolid; BPaLC – bedaquiline, pretomanid, linezolid, clofazimine; BPaLM – bedaquiline, pretomanid,

5 linezolid, moxifloxacin; DST – drug susceptibility testing; Mfx – Moxifloxacin; NHB – Net Health Benefit; QALY – Quality-adjusted Life Year;

6 UI – Uncertainty Interval; USD – United States Dollars; WTP – Willingness-to-Pay.

7 Strategies listed in order of increasing discounted total cost. Lower bound willingness-to-pay = 4,700 USD/QALY; upper bound willingness-to-

8 pay = 7,021 USD/QALY. Dominated strategies are those that were both more costly and resulted in poorer health than at least one other strategy,

9 based on point estimates. For nondominated strategies (i.e., strategy numbers 1, 5, and 7), the cheapest (Strategy 5) is listed as the comparator. For

10 strategies 1, 7 and 8, incremental discounted total cost and incremental discounted QALYs were calculated relative to the next cheapest,

11 nondominated strategy. The most cost-effective strategy is highlighted in **bold** text. Mean values are shown with accompanying 95% UIs in

12 parentheses.

13 \*Strategy (2) was dominated by extended dominance; ICER = 77,000 USD/QALY

14

15

16 **Fig 1. 6 months of BPaLM is cost-effective in treating RR-TB.**

17 (A) The cost-effectiveness plane shows point estimates for the discounted total costs and discounted QALYs under each modeled strategy. These  
18 are calculated as the mean of all simulation runs (1,000 second order Monte Carlo simulations, each with 10,000 individual patient simulations).  
19 The efficient frontier (black lines) connects the non-dominated strategies based on point estimates. (B) The cost-effectiveness acceptability curve  
20 displays the probability that each modeled strategy is the most cost-effective strategy at different levels of WTP. This probability is calculated as  
21 the proportion of 1,000 second-order Monte Carlo simulations where the respective strategy was optimal, given the value for WTP. Strategies  
22 were excluded if they were not cost-effective in any of the simulations (these were strategies 3, 4, and 6, where BPaL only was used if Mfx had to  
23 be stopped under a BPaLM regimen). Vertical dashed lines mark the lower and upper bounds of the WTP thresholds for Moldova.

24 \*Strategy (2) (6 months BPaLM, BPaLC if Mfx discontinued, DST upfront then every 1 month) was very close to the efficient frontier but was  
25 dominated by extended dominance based on point estimates.

26 BPaL, bedaquiline, pretomanid, linezolid; BPaLC, bedaquiline, pretomanid, linezolid, clofazimine; BPaLM, bedaquiline, pretomanid, linezolid,  
27 moxifloxacin; DST, drug susceptibility testing; FQ-R, fluoroquinolone-resistant; FQ-S, fluoroquinolone-susceptible; Mfx, moxifloxacin;  
28 QALY, quality-adjusted life year; USD, United States dollars; WTP, willingness-to-pay.

1 Strategy (5) (6-months BPaLM, second-line DST at 4 months and then every 4 months, BPaLC if Mfx  
2 stopped) had the lowest undiscounted lifetime total costs (\$8412, 95% UI: [6469, 10991]), followed by  
3 Strategy (1) and Strategy (2) (Table 3).

4 Compared to 6-month BPaLM-based strategies where BPaLC was used if Mfx had to be stopped,  
5 strategies continuing only the three-drug regimen BPaL (Strategies (3), (4), and (6)) resulted in worse  
6 overall health *and* additional lifetime total costs. The frequency of second-line DST did not lead to large  
7 differences in health or cost outcomes (Fig 1).

8 We compared cost-effectiveness ratios (ICERs) to current cost-effectiveness criteria for Moldova, with  
9 the willingness-to-pay for health improvements assumed to fall between \$4700 and \$7021 per QALY  
10 gained. According to this approach Strategy (1) (6-months BPaLM, DST upfront then every 4 months,  
11 BPaLC if Mfx stopped) was the most cost-effective strategy with an ICER of \$4375 per QALY.

12 Strategy (7) was potentially cost-effective, but only with a willingness to pay over \$56,100 per additional  
13 QALY, far higher than the upper bound threshold. In Fig 1B, we show the probability that each strategy is  
14 the most cost-effective for given cost-effectiveness thresholds.

15 Strategies (1), (2), and (5) had the highest probabilities of being cost-effective. All three are 6-month  
16 BPaLM strategies where BPaLC was continued for those stopping Mfx, and differ only based on the  
17 schedule of routine DST. Taken together, the probability that one of these strategies would be most cost-  
18 effective was at least 93% across the range of cost-effectiveness thresholds for Moldova.

19 For simplicity, we henceforth make comparisons between the leading (i.e., most cost-effective based on  
20 point estimates) 6-month BPaLM-based and standard of care-based strategies: Strategy (1) and Strategy  
21 (7), respectively. The category-specific costs for these strategies are shown in Fig 2, and the incremental  
22 cost-effectiveness for this one-to-one comparison in S7 Fig.

23



24 **Fig 2. Lifetime costs for 6 months BPaLM and Standard of Care strategies by category.**

25 Undiscounted lifetime costs per individual for Strategy (1) (6 months BPaLM, DST upfront, repeat DST  
26 every 4 months, BPaLC if Mfx stopped) as compared to Strategy (7) (standard of care 9-18 month  
27 regimens based on results of upfront DST, repeat DST every 4 months). The bars show the mean model  
28 outcomes for each cost category, with error bars representing 95% UIs.

29 BPaLC – bedaquiline, pretomanid, linezolid, clofazimine; BPaLM – bedaquiline, pretomanid, linezolid,  
30 moxifloxacin; DST – drug susceptibility testing; UI – uncertainty interval; USD – United States Dollars

31  
32 Compared to the standard of care (Strategy (7)), the incremental NHB of 6 months BPaLM (Strategy (1))  
33 was 0.656 QALYs; (95% UI [-0.091, 1.383] p=0.082) at the lower bound WTP and 0.419 QALYs; (95%  
34 UI [-0.206, 0.994] p=0.166) at the upper bound WTP.

35 **Drug resistance**

36 When counting time with resistance across the entire cohort, compared to Strategy (7), Strategy (1) was  
37 associated with a non-significant change in the mean duration with any RR-TB of -1.10 months; (95% UI  
38 [-4.07, 2.28] p=0.486) (Fig 3, S3 Table). Strategy (1) increased the mean duration with resistance to  
39 pretomanid by 0.55 months; (95% UI [0.20, 1.05] p<0.001) and delamanid by 0.54 months; (95% UI  
40 [0.18, 1.04] p=0.002) (Fig 3, S3 Table).

41  
42 **Fig 3. Effect of 6 months BPaLM on duration of resistance to key anti-TB drugs.**

43 Results are shown for Strategy (1) (6 months BPaLM, DST upfront, repeat DST every 4 months, BPaLC  
44 if Mfx stopped) as compared to Strategy (7) (standard of care 9-18 month regimens based on results of  
45 upfront DST, repeat DST every 4 months). For each drug, two estimates are provided: counting time with  
46 resistance at any point until the individual is truly cured (dark green), and counting time with resistance  
47 only while an individual has TB disease but is not being treated (light green). Both estimates are provided

48 per individual, averaged over the same denominator of the entire cohort initiating treatment. 95% UIs are  
49 shown by the accompanying error bars.

50 BPaLC – bedaquiline, pretomanid, linezolid, clofazimine; BPaLM – bedaquiline, pretomanid, linezolid,  
51 moxifloxacin; DST – drug susceptibility testing; Mfx, moxifloxacin; SOC – standard of care; TB –  
52 Tuberculosis; UI – Uncertainty Interval

53  
54 In contrast, Strategy (1) decreased the duration with resistance for several drugs: The mean change was -  
55 2.21 months for moxifloxacin (95% UI [-3.39, -1.02]  $p < 0.001$ ), -2.28 months for pyrazinamide (95% UI  
56 [-4.02, -0.52]  $p = 0.016$ ), -1.31 months for clofazimine (95% UI [-1.94, -0.80]  $p < 0.001$ ), -0.92 months for  
57 bedaquiline (95% UI [-1.48, -0.49]  $p < 0.001$ ), -0.95 months for cycloserine (95% UI [-1.38, -0.62]  
58  $p < 0.001$ ), and -0.40 months for amikacin (95% UI [-0.79, -0.06]  $p = 0.022$ ) (Fig 3, S3 Table). When  
59 measuring time with resistance only among those with active, untreated RR-TB, or when measuring  
60 lifetime cumulative incidence of resistance, the findings revealed a similar picture (Fig 3, S3 Table).

61

## 62 **Secondary outcomes**

63  
64 Under Strategy (7), the mean number of grade 4-5 SAEs ever experienced per individual was 0.265 (95%  
65 UI: 0.233, 0.300). Strategy (1) resulted in a mean number of grade 4-5 SAEs of 0.237 (95% UI [0.197,  
66 0.284]), conferring a decrease of 0.028 grade 4-5 SAEs per person (95% UI [-0.012, 0.063]  $p = 0.17$ ) over  
67 the course of treatment. Fig 4 displays the proportion ever experiencing a grade 4-5 SAE to each drug; the  
68 point estimates were lower for Strategy (1) than for Strategy (7) for all drugs except linezolid and  
69 pretomanid.

70

71

72 **Fig 4. Cumulative incidence of grade 4-5 Severe Adverse Events under 6 months BPaLM and**  
73 **Standard of Care.**

74 The mean cumulative incidence of Grade 4-5 Severe Adverse Events ever experienced to each of 12 anti-  
75 TB drugs is shown for Strategy (1) (6 months BPaLM, DST upfront, repeat DST every 4 months, BPaLC  
76 if Mfx stopped) as compared to Strategy (7) (standard of care 9-18 month regimens based on results of  
77 upfront DST, repeat DST every 4 months). Estimates are provided per individual, averaged over the entire  
78 cohort initiating treatment. The mean estimate is shown by the bar, with 95% UIs represented as error  
79 bars. BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; SAE – grade 4-5 Severe Adverse Event;  
80 TB – Tuberculosis; UI – Uncertainty Interval

81  
82 When health benefits were measured using life years unadjusted for health-related quality of life, strategy  
83 (7) again conferred a slightly higher life expectancy than strategy (1) on expectation. Also consistent with  
84 the primary QALY-based outcomes, the lowest life expectancy was estimated for Strategies (3), (4), and  
85 (6) (BPaLM-based strategies where BPaL was continued in the event of Mfx being stopped). (S4 Table).

86  
87 For the shorter-term endpoints of 6 months, 12 months, and 17 months (i.e., 72 weeks) from treatment  
88 initiation, we found that Strategy (1) resulted in a reduction in the composite unfavorable outcome  
89 compared to Strategy (7). The reduction was not significant when using the TB-PRACTECAL aligned  
90 definitions for unfavorable outcomes, but was significant and larger in magnitude when using WHO-  
91 based definitions (S5 Table, S9 Fig).

92 Compared to Strategy (7), Strategy (1) would be expected to save Moldova's national TB program budget  
93 \$7.1 million (95% UI: [1.3 million, 15.4 million]  $p=0.002$ ) over the five year period from implementation  
94 (S6 Table).

## 95 96 **Sensitivity Analyses**

97 Fig 5 shows how cost-effectiveness results change for different values of the hazard rate ratio (HRR) of  
98 cure, and the initial prevalence of fluoroquinolone resistance, for Strategy (1) as compared to Strategy (7).  
99 In these results, Strategy (1) was estimated to be cost-effective (i.e., had a positive Net Health Benefit)

100 compared to Strategy (7) across the range of values used for these parameters. Similarly, total costs were  
101 lower for Strategy (1) compared to Strategy (7) across the range of values assessed. Health outcomes  
102 were sensitive to the value of the HRR for cure for the BPaLM regimen as compared to standard of care  
103 regimens. For low values of the HRR (HRR = 1), Strategy (1) was estimated to lead to a mean 0.90  
104 reduction in QALYs. For high values (HRR = 2), Strategy (1) would lead to a mean 0.35 gain in QALYs.  
105 All data files containing these results are available in a repository.[62]

106

107 **Fig 5. Sensitivity analyses varying relative effectiveness of BPaLM and cohort prevalence of**  
108 **fluoroquinolone resistance.**

109 One-way sensitivity analyses exploring the implications of key model parameters, in terms of their effect  
110 on the incremental benefits and costs of Strategy (1) (6 months BPaLM, DST upfront, repeat DST every 4  
111 months, BPaLC if Mfx stopped) as compared to Strategy (7) (standard of care 9-18 month regimens based  
112 on results of upfront DST, repeat DST every 4 months). We chose to compare these two strategies as they  
113 were the best-performing BPaLM-based and standard of care-based strategies, respectively. In the left  
114 column, the HRR of cure for the BPaLM regimen compared to the standard of care is varied. In the right  
115 column, we vary the starting prevalence of fluoroquinolone resistance in the cohort (i.e., among all RR-  
116 TB). Each of the parameters is varied deterministically in the respective sensitivity analysis, with all other  
117 model parameters drawn as in the probabilistic sensitivity analysis. The outcomes quantified on the y-axis  
118 for each row of plots are (top to bottom): incremental NHB (calculated using discounted Total Costs and  
119 discounted QALYs at the lower bound WTP), incremental QALYs (undiscounted), and incremental Total  
120 Costs (undiscounted). The difference between the modeled outcomes under BPaLM and the standard of  
121 care is shown for 1,000 model runs, each an average of 10,000 individual patient simulations. The red line  
122 shows the trend as represented by regression of the y-axis variable on the x-axis variable, using a  
123 generalized additive model with cubic spline to obtain a restricted maximum likelihood within  
124 ggplot2.[58] The vertical dashed lines mark the base case assumptions for the mean of each of these  
125 model parameters. BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; FQ – Fluoroquinolone;

- 126 HRR – Hazard Rate Ratio; NHB – Net Health Benefit QALY – Quality-adjusted Life Year; RR-TB –  
127 Rifampicin-resistant tuberculosis

## 1 **DISCUSSION**

2 In this study we assessed the potential health impact and cost effectiveness of a 6-month BPaLM regimen  
3 for treating RR-TB in a setting with a high prevalence of drug resistance. Compared to a strategy using 9-  
4 18 month regimens based on the 2020 WHO treatment guidelines for drug-resistant TB, we found the 6-  
5 month BPaLM regimen would be cost-effective across a range of WTP thresholds, with substantial  
6 reductions in the duration and cost of treatment, but little expected change in health outcomes. Though  
7 there is considerable overlap between some of the 6-month BPaLM implementation scenarios, there is a  
8 clear lead for strategies where clofazimine is used to “top up” the regimen if moxifloxacin must be  
9 discontinued because of a grade 4-5 SAE or resistant DST result, compared to continuing on the three-  
10 drug BPaL regimen alone. Holding the drug regimen constant, the frequency of second-line DST (to  
11 fluoroquinolones and injectables using MGIT) did not result in substantial differences to health or cost  
12 outcomes.

13 Though our analysis was principally concerned with health outcomes over the lifetime horizon, our  
14 findings also show that 6 months of BPaLM reduces the risk of unfavorable outcomes over shorter time  
15 horizons, in line with the direction of effect observed at 72 weeks in the TB-PRACTECAL randomized  
16 controlled trial [8]. On cost-effectiveness specifically, our findings for Moldova are in line with a  
17 previous economic evaluation for populations across South Africa, Belarus, and Uzbekistan [28]. Belarus  
18 also has a high proportion of RR-TB among individuals newly diagnosed with TB [2], but we do not  
19 know whether the joint distribution of resistance to other important drugs would differ between Belarus  
20 and Moldova. Although South Africa and Uzbekistan have a lower prevalence of resistance to many  
21 drugs, we found that 6 months of BPaLM remained cost-effective when the proportion of RR-TB patients  
22 with FQ-R was varied across the wide range of 0-40% (compared to Moldova at 28%). Our analysis  
23 builds on the aforementioned cost-effectiveness analysis by explicitly modelling the acquisition of drug  
24 resistance, with the initial cohort resistance profile informed by genetic sequencing data from Moldova.  
25 We also investigated the potential effects of a larger number of policy implementation scenarios,

26 including the frequency of DST, and whether patients having to stop Mfx under BPaLM should continue  
27 on BPaL alone or continue on an alternative four-drug regimen.

28 When modeling the effectiveness estimate for BPaLM as compared to the standard of care, we assumed  
29 that the treatment effect for true cure in the model was approximated by the treatment effect for sputum  
30 culture conversion from the TB-PRACTECAL trial [8]. Although the trial measured clinical outcomes, its  
31 primary composite outcome measure combined treatment failure, discontinuation, LTFU, death and  
32 recurrence, outcomes that are important to distinguish to calculate long-term health outcomes. The  
33 numbers of individuals experiencing each of the long-term outcomes of greatest clinical interest were  
34 very small. Even if the effect on true cure is not the same as on culture conversion, we found that 6-  
35 months BPaLM remained the cost-effective strategy when the HRR (point estimate: 1.59) was varied over  
36 a wide range.

37 While both regimens perform best at lower levels of resistance, sensitivity analyses showed that 6 months  
38 of BPaLM may result in a reduction in total QALYs as compared to the standard of care at lower levels of  
39 initial FQ-R, or if the BPaLM regimen has lower comparative effectiveness than estimated in the TB-  
40 PRACTECAL trial, even while it provides overall value for money. Although policymakers may be  
41 uncomfortable adopting interventions that reduce health benefit on expectation, this difference was not  
42 statistically significant. Adopting the new regimen would bring substantial benefits in the form of reduced  
43 regimen duration, and freeing up funding to spend on other health interventions.

44 In this analysis we found that 6 months of BPaLM improved or resulted in no change to the duration of  
45 disease with resistant strains of *M. tuberculosis* as well as the cumulative incidence of resistance for all  
46 anti-TB drugs investigated, except pretomanid and delamanid. Both the duration and cumulative  
47 incidence measures were influenced by the starting profile of resistance as informed by the WGS data, the  
48 rate of acquisition of new resistance to each drug under each modeled drug regimen, and the monthly rate  
49 of cure. Changes in the rate of acquisition of resistance are important for individuals undergoing treatment  
50 today (some of the effects of this are captured in the QALYs estimated under each strategy) but

51 preventing new second-line resistance is also important for the health outcomes of those living with RR-  
52 TB in the future.

53 This analysis had several limitations. The Moldovan genomic data used to characterize the resistance  
54 profile in the modeled population were from culture positive sputum specimens in 2018-19, and so may  
55 not accurately describe current resistance patterns in Moldova or resistance elsewhere, although we hope  
56 the sensitivity analysis on the prevalence of FQ-R aids in the generalization of findings. Because the  
57 publicly-available WGS dataset excluded samples with mixed strains of *M. tuberculosis* (17.4%), it is  
58 possible that our findings do not adequately address this subpopulation with mixed infections, although  
59 we note that all the remaining model parameters reflect the real-world health outcomes and costs of a mix  
60 of mono- and mixed-strain infections. Furthermore, we assumed that that the true resistance profile was  
61 perfectly predicted by the presence or absence of mutations conferring resistance in this data: While the  
62 sensitivity and specificity of genomic sequencing is very high for detecting resistance in rifampicin,  
63 isoniazid, and ethambutol, the performance is less favorable for moxifloxacin, amikacin, and ethionamide  
64 [63].

65 There are also limitations pertaining to the simulation of health and cost outcomes. The hazard rate ratio  
66 for cure was based on the outcome of sputum culture conversion from TB-PRACTECAL; while culture  
67 conversion is indeed a prognostic marker in TB [64], it is not a perfect substitute to quantify the rate of  
68 true cure, which is unobservable. Further, real-world outcomes with 6-months of BPaLM are likely to be  
69 less favorable than in the high-fidelity environment of a randomized controlled trial—for example, there  
70 may have been a higher frequency of follow-up in the trial—and the status quo may differ between  
71 settings. We did not explicitly model the differences in adherence that may exist between regimens, and  
72 we made the simplifying assumption that increasing the number of effective drugs increases the monthly  
73 rate of cure and reduces the rate of acquiring resistance. This was based on a previously applied approach  
74 [7] and is likely to hold qualitatively, but we did not account for the all the differences that may exist  
75 between specific drugs, and the interactions between them. For example, the effectiveness of BPaLC vs.  
76 BPaL may not be the same as the effectiveness of BPaLM vs. BPaL, yet—SAEs aside—the modeling



77 approach was agnostic to this, conditional on the number of “effective” drugs in the regimen. For  
78 parsimony, we did not explicitly model changes in smear status. For individuals no longer receiving  
79 treatment, we adopted a mortality rate estimate for smear-positive TB, which may overestimate mortality  
80 specifically for those who appear to have completed treatment successfully but not truly cured; this would  
81 likely bias the results against shorter, 6-month BPaLM strategies. While the relationship between HIV  
82 and RR-TB treatment outcomes is neither straight-forward nor consistent [38,65], we did not model HIV  
83 status at the individual level and as such we were unable to comment specifically on health outcomes for  
84 those with TB-HIV coinfection. Although the probability of a grade 4-5 SAE was modelled separately for  
85 each drug, we did not incorporate variation in the duration and consequences of each type of SAE.  
86 Finally, we did not account for the secondary effects resulting from onward transmission of RR-TB, and  
87 our results may therefore not capture the full cost-effectiveness implications of each modelled strategy.  
88 To account for this explicitly, it would be necessary to model the transmission dynamics of *M.*  
89 *tuberculosis*. Instead, we estimated the cumulative incidence and duration of resistance as surrogates for  
90 the long-term health outcomes they may affect, insofar as lower incidence and fewer months of resistant  
91 disease might each result in less transmission of resistant strains.  
92 This study was conducted in the setting of Moldova, a country with a high proportion of RR-TB with  
93 resistance to second-line drugs. By conducting sensitivity analysis on the proportion with FQ-R, we  
94 aimed to aid the generalization of findings to other settings. Many of the health-related model parameters  
95 are also generalizable beyond Moldova: TB outcomes under the standard of care were informed by multi-  
96 national meta-analyses, and the estimate for comparative effectiveness was from a multi-national trial (S1  
97 Table). However, many of the cost parameters were from Moldova and Georgia (GDP per capita of  
98 \$5,563 and \$6,628 in 2022, respectively) [66], and so there are likely limitations in the generalization of  
99 incremental costs of 6 months BPaLM compared to the standard of care, especially to countries with very  
100 different income levels.  
101 To optimize clinical care for RR-TB, decision makers must take account of important health and  
102 economic effects for affected individuals as well as society at large. In this study, we estimated favorable

103 cost-effectiveness for the 6-month BPaLM regimen in settings with a high burden of drug resistance,  
104 conditional on BPaLC being used in the event of moxifloxacin being contraindicated, rather than BPaL  
105 alone. The schedule of second-line DST did not appear to affect health outcomes or costs to a great  
106 degree across the finite number of DST schedules we explored, and further analyses may be warranted to  
107 explore the optimal testing frequency in Moldova and other settings—especially where second-line DST  
108 capacity is limited or unavailable [67]—and to explore additional technologies beyond MGIT for  
109 identifying resistance to fluoroquinolones and injectables. The forthcoming results of the endTB trial [9–  
110 13] will expand the evidence base for shorter regimens, and while the trial investigated 9- as opposed to  
111 the 6-month regimens investigated in this study, this still represents a substantial shortening compared to  
112 many standard of care regimens. The growing body of both empirical and modeling literature may also  
113 highlight the elements of treating RR-TB—including the choice of drugs, duration of regimen, and  
114 frequency and modality of DST—which overall provide the best treatment strategy, for each patient’s  
115 specific needs. Clinical and health policy decisions alike would be enhanced by continued collective  
116 efforts to strengthen the evidence base in the ways most likely to optimize care, with sufficient numbers  
117 of patients to quantify long-term health outcomes across multiple settings.

## 1 **Acknowledgments**

2 For helpful feedback on research-in-progress presentations, LPJ would like to thank current and former  
3 students, postdocs and faculty affiliated with: the Center for Health Decision Science, the PhD Program in  
4 Health Policy, and the Center for AIDS Research, all at Harvard University, Cambridge, MA, USA; the  
5 Decision Science Methods Group at Erasmus University, Rotterdam, the Netherlands.

6

## 7 **Author Contributions**

8	Conceptualization:	LPJ, NAM, TC, JF, SS, RY, VC, NC, AC
9	Data curation:	LPJ, TC, NAM
10	Formal Analysis:	LPJ, NAM
11	Funding Acquisition:	LPJ, NAM, TC
12	Investigation:	LPJ, NAM, TC, MFF
13	Methodology:	LPJ, NAM, SS, RY
14	Project Administration:	LPJ, NAM
15	Resources:	LPJ, NAM
16	Software:	LPJ, NAM, FK
17	Supervision:	NAM, TC
18	Validation:	LPJ, TC, MFF, NAM, DC, JF, VC
19	Visualization:	LPJ, FK, NAM
20	Writing – Original Draft:	LPJ, NAM
21	Writing – Review & Editing:	LPJ, NAM, MFF, TC, JF, FK, SS, RY, DC, NC, VC, AC

22

23

24

25

26 **Abbreviations**

27 BPaL, bedaquiline, pretomanid, linezolid; BPaLC, bedaquiline, pretomanid, linezolid, clofazimine;  
28 BPaLM, bedaquiline, pretomanid, linezolid, moxifloxacin; CDF – cumulative distribution function; CI –  
29 confidence interval; CrI – credibility interval; CPI – Consumer Price Index; DST – drug susceptibility  
30 testing; FQ-R, fluoroquinolone-resistant; FQ-S, fluoroquinolone-susceptible; LJ – Lowenstein-Jensen;  
31 MDL – Moldovan Leu; GDP – Gross Domestic Product; GEL – Georgian Lei; HIV – human  
32 immunodeficiency virus; LTFU – lost to follow up; LY – Life Year; *M. tb.* – *Mycobacterium*  
33 *tuberculosis*; MDR-TB – multidrug-resistant tuberculosis; NHB – Net Health Benefit; QALY – Quality-  
34 adjusted Life Year; RR-TB – rifampicin-resistant tuberculosis; SAE – grade 4-5 Severe Adverse Event;  
35 SEM – Standard Error of the Mean; SMR – standardized mortality ratio; TB – tuberculosis; UI –  
36 Uncertainty Interval; USD – United States Dollars; WTP – Willingness-to-Pay; XDR-TB – extensively  
37 drug-resistant tuberculosis.

## REFERENCES

1. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. [date accessed: 29 Mar 2023]. Available: <https://www.who.int/publications/i/item/9789240063129>
2. WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. World Health Organization; 2020. Available: <https://www.who.int/publications-detail-redirect/9789240007048>
3. Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, Brode S, et al. Standardised shorter regimens *versus* individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. *Eur Respir J*. 2020;55: 1901467. doi:10.1183/13993003.01467-2019
4. Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2019;71: 2336–2344. doi:10.1093/cid/ciz1107
5. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis. *N Engl J Med*. 2022;387: 810–823. doi:10.1056/NEJMoa2119430
6. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis. *N Engl J Med*. 2020;382: 893–902. doi:10.1056/NEJMoa1901814
7. Kendall EA, Malhotra S, Cook-Scalise S, Denkinger CM, Dowdy DW. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations. *BMC Infect Dis*. 2019;19. doi:10.1186/s12879-019-4429-x
8. Nyang’wa B-T, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. *N Engl J Med*. 2022;387: 2331–2343. doi:10.1056/NEJMoa2117166
9. endTB clinical trial results | endTB. [date accessed: 21 Nov 2023]. Available: <https://endtb.org/endtb-clinical-trial-results>
10. Mitnick CD. endTB trial: Design and baseline characteristics of participants in a study of five all-oral, shortened regimens for MDR/RR-TB. TBUnion; 2023 Nov 15; Paris. Available: [https://documents.theunion.org/web-uploads/UNION2023\\_Abstracts\\_High.pdf?\\_gl=1\\*1kgeq4f\\*\\_ga\\_8PZRTR8JPW\\*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA..](https://documents.theunion.org/web-uploads/UNION2023_Abstracts_High.pdf?_gl=1*1kgeq4f*_ga_8PZRTR8JPW*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA..)

11. Khan U. endTB trial: Efficacy results in a study of five all-oral, shortened regimens for MDR/RR-TB. TBUnion; 2023 Nov 15; Paris. Available: [https://documents.theunion.org/web-uploads/UNION2023\\_Abstracts\\_High.pdf?\\_gl=1\\*1kgeq4f\\*\\_ga\\_8PZRTR8JPW\\*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA..](https://documents.theunion.org/web-uploads/UNION2023_Abstracts_High.pdf?_gl=1*1kgeq4f*_ga_8PZRTR8JPW*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA..)
12. Guglielmetti L. endTB trial: Safety results in a study of five shortened, all-oral regimens for MDR/RR-TB. TBUnion; 2023 Nov 15; Paris. Available: [https://documents.theunion.org/web-uploads/UNION2023\\_Abstracts\\_High.pdf?\\_gl=1\\*1kgeq4f\\*\\_ga\\_8PZRTR8JPW\\*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA..](https://documents.theunion.org/web-uploads/UNION2023_Abstracts_High.pdf?_gl=1*1kgeq4f*_ga_8PZRTR8JPW*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA..)
13. Velásquez G. endTB trial sub-studies: Evidence on resistance and pharmacokinetics/pharmacodynamics to inform practice. TBUnion; 2023 Nov 15; Paris. Available: [https://documents.theunion.org/web-uploads/UNION2023\\_Abstracts\\_High.pdf?\\_gl=1\\*1kgeq4f\\*\\_ga\\_8PZRTR8JPW\\*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA..](https://documents.theunion.org/web-uploads/UNION2023_Abstracts_High.pdf?_gl=1*1kgeq4f*_ga_8PZRTR8JPW*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA..)
14. Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. *Lancet Respir Med*. 2020;8: 383–394. doi:10.1016/S2213-2600(20)30047-3
15. Thomas BE, Shanmugam P, Malaisamy M, Ovung S, Suresh C, Subbaraman R, et al. Psycho-Socio-Economic Issues Challenging Multidrug Resistant Tuberculosis Patients: A Systematic Review. *PLOS ONE*. 2016;11: e0147397. doi:10.1371/journal.pone.0147397
16. Isaakidis P, Rangan S, Pradhan A, Lodomirskaja J, Reid T, Kielmann K. “I cry every day”: experiences of patients co-infected with HIV and multidrug-resistant tuberculosis. *Trop Med Int Health TM IH*. 2013;18: 1128–1133. doi:10.1111/tmi.12146
17. Morris MD, Quezada L, Bhat P, Moser K, Smith J, Perez H, et al. Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: a patient’s perspective. *Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis*. 2013;17: 954–960. doi:10.5588/ijtld.12.0480
18. Mauch V, Melgen R, Marcelino B, Acosta I, Klinkenberg E, Suarez P. Tuberculosis patients in the Dominican Republic face severe direct and indirect costs and need social protection. *Rev Panam Salud Publica Pan Am J Public Health*. 2013;33: 332–339. doi:10.1590/s1020-49892013000500004
19. Kendall EA, Theron D, Franke MF, van Helden P, Victor TC, Murray MB, et al. Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study. *PloS One*. 2013;8: e83480. doi:10.1371/journal.pone.0083480
20. Global Drug Facility (GDF) Medicines Catalog. Stop TB Partnership; 2022. Available: [https://www.stoptb.org/sites/default/files/gdfmedicinescatalog\\_1.pdf](https://www.stoptb.org/sites/default/files/gdfmedicinescatalog_1.pdf)

21. Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment. In: TB Alliance [Internet]. [date accessed: 17 Jun 2023]. Available: <https://www.tballiance.org.za/news/price-reduction-paves-the-way-for-expanded-access-to-highly-effective-multidrug-resistant-tuberculosis-treatment>
22. Kaniga K, Hasan R, Jou R, Vasiliauskienė E, Chuchottaworn C, Ismail N, et al. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates. *J Clin Microbiol.* 2022;60: e02919-20. doi:10.1128/JCM.02919-20
23. Dheda K, Gumbo T, Lange C, Horsburgh CR, Furin J. Pan-tuberculosis regimens: an argument against. *Lancet Respir Med.* 2018;6: 240–242. doi:10.1016/S2213-2600(18)30097-3
24. zur Wiesch PA, Kouyos R, Engelstädter J, Regoes RR, Bonhoeffer S. Population biological principles of drug-resistance evolution in infectious diseases. *Lancet Infect Dis.* 2011;11: 236–247. doi:10.1016/S1473-3099(10)70264-4
25. Vanino E, Granozzi B, Akkerman OW, Munoz-Torrico M, Palmieri F, Seaworth B, et al. Update of drug-resistant tuberculosis treatment guidelines: A turning point. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis.* 2023; S1201-9712(23)00089–9. doi:10.1016/j.ijid.2023.03.013
26. Practical manual on tuberculosis laboratory strengthening, 2022 update. [date accessed: 21 Nov 2023]. Available: <https://www.who.int/publications-detail-redirect/9789240061507>
27. Pai M, Palamoukian KM. New tuberculosis technologies: challenges for retooling and scale-up [State of the art series. New tools. Number 4 in the series]. *Int J Tuberc Lung Dis.* 2012;16: 1281–1290. doi:10.5588/ijtld.12.0391
28. Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, Dodd M, et al. Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis. *PLOS Glob Public Health.* 2022;2: e0001337. doi:10.1371/journal.pgph.0001337
29. Global tuberculosis report 2020. [date accessed: 4 Apr 2023]. Available: <https://www.who.int/publications/i/item/9789240013131>
30. Yang C, Sobkowiak B, Naidu V, Codreanu A, Ciobanu N, Gunasekera KS, et al. Phylogeography and transmission of *M. tuberculosis* in Moldova. 2021 Jul p. 2021.06.30.21259748. doi:10.1101/2021.06.30.21259748
31. Download: The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop by the Institute of Medicine and the Russian Academy of Medical Science | The National Academies Press. [date accessed: 21 Nov 2023]. Available: <https://nap.nationalacademies.org/download/13033>



32. Stuckler D, Basu S, McKee M, King L. Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries. *Proc Natl Acad Sci*. 2008;105: 13280–13285. doi:10.1073/pnas.0801200105
33. Yang C, Sobkowiak B, Naidu V, Codreanu A, Ciobanu N, Gunasekera KS, et al. Phylogeography and transmission of *M. tuberculosis* in Moldova: A prospective genomic analysis. *PLOS Med*. 2022;19: e1003933. doi:10.1371/journal.pmed.1003933
34. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. [date accessed: 2 Mar 2023]. Available: <https://www.who.int/publications-detail-redirect/9789240063129>
35. ID 736718 - BioProject - NCBI. [date accessed: 9 Feb 2023]. Available: <https://www.ncbi.nlm.nih.gov/ezp-prod1.hul.harvard.edu/bioproject/PRJNA736718>
36. Ragonnet R, Flegg JA, Brilleman SL, Tiemersma EW, Melsew YA, McBryde ES, et al. Revisiting the Natural History of Pulmonary Tuberculosis: A Bayesian Estimation of Natural Recovery and Mortality Rates. : 9.
37. Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2019;19: 1129–1137. doi:10.1016/S1473-3099(19)30309-3
38. Bastos ML, Lan Z, Menzies D. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. *Eur Respir J*. 2017;49. doi:10.1183/13993003.00803-2016
39. Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Walt MVD, Kvasnovsky C, et al. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study. *PLOS Med*. 2015;12: e1001932. doi:10.1371/journal.pmed.1001932
40. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis. *Ann Intern Med*. 2008;149: 123–134. doi:10.7326/0003-4819-149-2-200807150-00008
41. Hunink MGM. Decision making in health and medicine: integrating evidence and values. Second edition. Cambridge: University Press; 2014.
42. Weinstein MC, Stason WB. Foundations of Cost-Effectiveness Analysis for Health and Medical Practices. *N Engl J Med*. 1977;296: 716–721. doi:10.1056/NEJM197703312961304
43. Feeny D, Krahn M, Prosser L, Salomon JA. Valuing Health Outcomes. 2nd ed. Cost-effectiveness in Health and Medicine. 2nd ed. Oxford University Press; 2016. pp. 167–200. Available: [https://hollis.harvard.edu/primo-explore/fulldisplay?docid=TN\\_cdi\\_proquest\\_ebookcentralchapters\\_4740819\\_18\\_202&cont](https://hollis.harvard.edu/primo-explore/fulldisplay?docid=TN_cdi_proquest_ebookcentralchapters_4740819_18_202&cont)



ext=PC&vid=HVD2&lang=en\_US&search\_scope=everything&adaptor=primo\_central\_multiple\_fe&tab=everything&query=any,contains,neumann%20cost-effectiveness

44. Weinstein MC, Torrance G, McGuire A. QALYs: The Basics. *Value Health*. 2009;12: S5–S9. doi:10.1111/j.1524-4733.2009.00515.x
45. Portnoy A, Yamanaka T, Nguhiu P, Nishikiori N, Garcia Baena I, Floyd K, et al. Costs incurred by people receiving tuberculosis treatment in low-income and middle-income countries: a meta-regression analysis. *Lancet Glob Health*. 2023;11: e1640–e1647. doi:10.1016/S2214-109X(23)00369-8
46. Meltzer DO, Basu A, Sculpher MJ. Theoretical Foundations of Cost-Effectiveness Analysis in Health and Medicine. In: Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE, editors. *Cost-Effectiveness in Health and Medicine*. Oxford University Press; 2016. p. 0. doi:10.1093/acprof:oso/9780190492939.003.0002
47. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. *BMJ Glob Health*. 2018;3: e000964. doi:10.1136/bmjgh-2018-000964
48. Paulden M. Why it’s Time to Abandon the ICER. *Pharmacoeconomics*. 2020;38: 781–784. doi:10.1007/s40273-020-00915-5
49. Husereau D, Drummond M, Augustovski F, De Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. *Value Health*. 2022;25: 10–31. doi:10.1016/j.jval.2021.10.008
50. Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. *Value Health J Int Soc Pharmacoeconomics Outcomes Res*. 2012;15: 835–842. doi:10.1016/j.jval.2012.04.014
51. TreeAge Pro Healthcare 2023. TreeAge Software, Williamstown, MA; Available: <http://www.treeage.com>
52. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.; 2022. Available: <https://www.R-project.org/>
53. Warnes GR, Bolker B, Gorjanc G, Grothendieck G, Korosec A, Lumley T, et al. gdata: Various R Programming Tools for Data Manipulation. 2022. Available: <https://cran.r-project.org/web/packages/gdata/index.html>
54. Wickham H, RStudio. tidyverse: Easily Install and Load the “Tidyverse.” 2023. Available: <https://cran.r-project.org/web/packages/tidyverse/index.html>
55. Wickham H, RStudio. stringr: Simple, Consistent Wrappers for Common String Operations. 2022. Available: <https://cran.r-project.org/web/packages/stringr/index.html>

56. Robinson D, Hayes A, Couch [aut S, cre, Software P, PBC, et al. broom: Convert Statistical Objects into Tidy Tibbles. 2023. Available: <https://cran.r-project.org/web/packages/broom/index.html>
57. Wickham H, François R, Henry L, Müller K, Vaughan D, Software P, et al. dplyr: A Grammar of Data Manipulation. 2023. Available: <https://cran.r-project.org/web/packages/dplyr/index.html>
58. Kassambara A. ggpubr: “ggplot2” Based Publication Ready Plots. 2023. Available: <https://cran.r-project.org/web/packages/ggpubr/index.html>
59. Garnier S, Ross N, Rudis B, Sciaini M, Camargo AP, Scherer C. viridis: Colorblind-Friendly Color Maps for R. 2021. Available: <https://cran.r-project.org/web/packages/viridis/index.html>
60. Firke S, Denney B, Haid C, Knight R, Grosser M, Zadra J. janitor: Simple Tools for Examining and Cleaning Dirty Data. 2023. Available: <https://cran.r-project.org/web/packages/janitor/index.html>
61. Wickham H. reshape2: Flexibly Reshape Data: A Reboot of the Reshape Package. 2020. Available: <https://cran.r-project.org/web/packages/reshape2/index.html>
62. James LP. lyndonjames/BPaLM\_Moldova. [date accessed: 22 Jan 2024]. Available: [https://github.com/lyndonjames/BPaLM\\_Moldova/tree/main](https://github.com/lyndonjames/BPaLM_Moldova/tree/main)
63. The CRyPTIC Consortium. A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics. Ladner J, editor. PLOS Biol. 2022;20: e3001721. doi:10.1371/journal.pbio.3001721
64. Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med. 2015;3: 201–209. doi:10.1016/S2213-2600(15)00036-3
65. Sergeev R, Colijn C, Murray M, Cohen T. Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Sci Transl Med. 2012;4: 135ra67. doi:10.1126/scitranslmed.3003815
66. World Bank Open Data. Available: <https://data.worldbank.org/>
67. Wallis RS, Cohen T, Menzies NA, Churchyard G. Pan-tuberculosis regimens: an argument for. Lancet Respir Med. 2018;6: 239–240. doi:10.1016/S2213-2600(18)30096-1
68. Global Tuberculosis Programme. Tuberculosis Data. 2023. Available: <https://www.who.int/teams/global-tuberculosis-programme/data>

69. Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, et al. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. *Antimicrob Agents Chemother*. 2015;59: 129–135. doi:10.1128/AAC.03822-14
70. Liu Y, Gao J, Du J, Shu W, Wang L, Wang Y, et al. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2021;102: 392–396. doi:10.1016/j.ijid.2020.10.081
71. Nambiar R, Tornheim JA, Diricks M, Bruyne KD, Sadani M, Shetty A, et al. Linezolid resistance in *Mycobacterium tuberculosis* isolates at a tertiary care centre in Mumbai, India. *Indian J Med Res*. 2021;154: 85–89. doi:10.4103/ijmr.IJMR\_1168\_19
72. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. *N Engl J Med*. 2012;367: 1508–1518. doi:10.1056/NEJMoa1201964
73. Kohli-Lynch CN. Probabilistic sensitivity analysis and value of information analysis. 1st ed. In: Bishai D, Brenzel L, Padula W, editors. *Handbook of Applied Health Economics in Vaccines*. 1st ed. Oxford University Press Oxford; 2023. pp. 290–309. doi:10.1093/oso/9780192896087.003.0024
74. Blöndal K, Viiklepp P, Guðmundsson LJ, Altraja A. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis. *Int J Tuberc Lung Dis*. 2012;16: 1228–1233. doi:10.5588/ijtld.12.0037
75. *World Population Prospects*. UN Population Division, Department of Economic and Social Affairs.; 2019. Available: [https://population.un.org/wpp/Download/Files/1\\_Indicators%20\(Standard\)/EXCEL\\_FILES/3\\_Mortality/WPP2019\\_MORT\\_F15\\_1\\_LIFE\\_TABLE\\_SURVIVORS\\_BOTH\\_SEXES.xlsx](https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/EXCEL_FILES/3_Mortality/WPP2019_MORT_F15_1_LIFE_TABLE_SURVIVORS_BOTH_SEXES.xlsx)
76. Walker IF, Shi O, Hicks JP, Elsey H, Wei X, Menzies D, et al. Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients. *Eur Respir J*. 2019;54. doi:10.1183/13993003.00353-2018
77. A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India. *Bull World Health Organ*. 1960;23: 535–585.
78. Gils T, Lynen L, de Jong BC, Van Deun A, Decroo T. Pretomanid for tuberculosis: a systematic review. *Clin Microbiol Infect*. 2022;28: 31–42. doi:10.1016/j.cmi.2021.08.007
79. Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliuskas S, Kuksa L, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. *Eur Respir J*. 2019;54. doi:10.1183/13993003.01522-2019

80. Schnippel K, Firnhaber C, Berhanu R, Page-Shipp L, Sinanovic E. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa. *Int J Tuberc Lung Dis*. 2018;22: 393–398. doi:10.5588/ijtld.17.0661
81. Bauer M, Ahmed S, Benedetti A, Greenaway C, Lalli M, Leavens A, et al. The impact of tuberculosis on health utility: a longitudinal cohort study. *Qual Life Res*. 2015;24: 1337–1349. doi:10.1007/s11136-014-0858-6
82. Takahara M, Katakami N, Shiraiwa T, Abe K, Ayame H, Ishimaru Y, et al. Evaluation of health utility values for diabetic complications, treatment regimens, glycemic control and other subjective symptoms in diabetic patients using the EQ-5D-5L. *Acta Diabetol*. 2019;56: 309–319. doi:10.1007/s00592-018-1244-6
83. Chikovani I, Shengelia N, Marjanishvili N, Gabunia T, Khonelidze I, Cunnama L, et al. Cost of TB services in the public and private sectors in Georgia (No 2). *Int J Tuberc Lung Dis*. 2021;25: 1019–1027. doi:10.5588/ijtld.21.0176
84. Cates L, Crudu V, Codreanu A, Ciobanu N, Fosburgh H, Cohen T, et al. Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting. *Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis*. 2021;25: 228–230. doi:10.5588/ijtld.20.0586
85. Myambutol (ethambutol) dosing, indications, interactions, adverse effects, and more. [date accessed: 18 Feb 2023]. Available: <https://reference.medscape.com/drug/myambutol-ethambutol-342677>
86. pyrazinamide: Dosing, contraindications, side effects, and pill pictures - epocrates online. [date accessed: 18 Feb 2023]. Available: <https://online.epocrates.com/drugs/279/pyrazinamide>
87. Sweeney S, Cunnama L, Laurence Y, Garcia Baena I, Kairu A, Minyewelet M, et al. Value TB Dataset: costs per intervention. *Harvard Dataverse*; 2021. doi:10.7910/DVN/QOI6IR
88. UNdata | record view | Life expectancy at birth for both sexes combined (years). [date accessed: 24 Mar 2022]. Available: <http://data.un.org/Data.aspx?q=moldova&d=PopDiv&f=variableID%3A68%3BcrID%3A498>
89. xe.com Currency Charts. Available: <https://www.xe.com/currencycharts/>
90. World Bank International Comparisons Project. [date accessed: 21 Mar 2022]. Available: <https://databank.worldbank.org/embed/ICP-2017-Cycle/id/4add74e?inf=n>
91. Tekin K, Albay A, Simsek H, Sig AK, Guney M. Evaluation of the BACTEC MGIT 960 SL DST Kit and the GenoType MTBDRsl Test for Detecting Extensively Drug-resistant Tuberculosis Cases. *Eurasian J Med*. 2017;49: 183–187. doi:10.5152/eurasianjmed.2017.17040

92. Devasia RA, Blackman A, May C, Eden S, Smith T, Hooper N, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother. 2009;63: 1173–1178. doi:10.1093/jac/dkp096

## **S1 Checklist. CHEERS 2022 Checklist.**

### **S1 Appendix. Additional Detail on Microsimulation Model.**

Here we provide an enhanced level of detail on some of the model structure. Specific elements reference sources from the literature [2,41,48,68–73].

### **S2 Appendix. Additional Detail on Calculated Model Parameters.**

Here we provide notation for how specific model parameters were derived from published sources [38,74].

#### **S1 Table. Model input parameters, complete set.**

CDF – cumulative distribution function; CI – confidence interval; CrI – credibility interval; CPI – Consumer Price Index; DST – drug susceptibility testing; LJ – Lowenstein-Jensen; MDL – Moldovan Leu; GDP – Gross Domestic Product; GEL – Georgian Lei; LTFU – lost to follow up; M. tb. – mycobacterium tuberculosis; NHB – Net Health Benefit; QALY – Quality-adjusted Life Year; SAE – Severe Adverse Event; SEM – Standard Error of the Mean; SMR – standardized mortality ratio; UI – Uncertainty Interval; USD – United States Dollars; WTP – Willingness-to-Pay.

\*denotes a parameter where there was no readily available measure of dispersion. For these parameters, we assumed a standard deviation equal to one third of the mean.

Parameter details are accompanied by citations from the literature [8,14,20,36–40,45,47,66,68,74–92].

#### **S2 Table. Probability of loss to follow up by month of treatment.**

LTFU – Lost to Follow Up.

LTFU data from Walker et al. 2019 [76]. \*The values in the rightmost column are used as the model inputs. Compared to the fourth column, we rounded down the values from month 21 onwards such that the probability of LTFU is zero thenceforth.

**S3 Table. Duration and cumulative incidence of resistance to key drugs.**

BPaLM, bedaquiline, pretomanid, linezolid, moxifloxacin; SOC, standard of care.

The entire cohort had RR-TB, and so the duration with rifampicin resistance is equivalent to the duration with active RR-TB, and the cumulative incidence of rifampicin resistance is not applicable. Some drugs were used very sparingly, if ever, under one or both strategies (e.g., amikacin, ethambutol, ethionamide, isoniazid, and pyrazinamide); as such the cumulative incidence may be very low for these drugs under one or both strategies.

**S4 Table. Life Years achieved under each RR-TB treatment strategy.**

BPaL – bedaquiline, pretomanid, linezolid; BPaLC – bedaquiline, pretomanid, linezolid, clofazimine;

BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; UI – Uncertainty Interval.

Strategies are listed in the same order as Table 3. Mean values are shown with accompanying 95% UIs in parentheses.

**S5 Table. Comparing outcomes at 6 months, 12 months, and 72 weeks from treatment initiation.**

BPaLC – bedaquiline, pretomanid, linezolid, clofazimine; BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; LYs – Life Years; Mfx – moxifloxacin; p.p. – percentage points; QALYs – Quality-adjusted Life Years; UI – Uncertainty Interval; WHO – World Health Organization

The following health outcomes are shown: a composite “Unfavorable outcome” closely aligned to the composite trial endpoint in TB-PRACTECAL, true cure, and quality-adjusted life expectancy. Results are shown separately over three model-run time horizons: 6 months, 72 weeks (in line with the endpoint in TB-PRACTECAL), and lifetime (in line with the primary outcomes in our analysis).

**S6 Table. Five-year budget impact of implementing 6 months of BPaLM in Moldova.**

TB – tuberculosis.

The budget impact was estimated for 6 months BPaLM (Strategy (1)) as compared to standard of care (Strategy (7))

### **S1 Fig. Schematic of the initial workup phase for the standard of care**

Both standard of care strategies (Strategy 7 and Strategy 8) are modeled on the recommended workup and regimen selection in the 2020 WHO guidelines on the treatment of drug-resistant tuberculosis [2]. We assumed that DST results (by MGIT) are available in 2 weeks. \*While we include the BPaL regimen as per the guidelines, no patients actually met the criteria to receive it under the standard of care (Strategies 7 and 8) in our model (i.e., in all model simulations, it is possible to adopt a WHO longer regimen). BPaL – bedaquiline, pretomanid, linezolid; DST – drug susceptibility test; FQ – fluoroquinolone; MGIT – Mycobacterial Growth Indicator Tube; WHO – World Health Organization

### **S2 Fig. *M. tb.* genomic sequencing data exclusion criteria.**

\*The full dataset did not include any samples with mixed strains of *M. tb.*

Exclusions made to the genomic sequencing drug susceptibility testing dataset are shown along with the number of observations. This dataset is described elsewhere [30,35]. The presence of a mutation conferring resistance to rifampicin was assumed to convey full resistance, and vice versa.

TB – tuberculosis.

### **S3 Fig. The rate of acquiring drug resistance.**

The modeled point estimate for the monthly rate that an individual's strain of *M. tuberculosis* will acquire resistance to each effective drug it is exposed to is plotted, conditional on that individual beginning the



month with  $n$  effective drugs in the regimen (x-axis). Estimates for 1, 3 and 4 effective drugs were obtained from the literature. The estimate for 2 drugs was calculated, assuming an additive risk (i.e., the increase in risk for 2 effective drugs compared to 3 is the same as the increase in risk for 3 effective drugs compared to 4). See also S1 Table.

#### **S4 Fig. Markov state-transition diagram.**

Transitions between states can occur as shown by the arrows. Though not receiving treatment, individuals in the “Active TB, no longer receiving treatment” state are subject to a low rate of self-cure, and so may still transition to the “Cured post-treatment” state. Asterisks (\*) highlight the major mechanisms through which the choice of treatment intervention affects outcomes. LTFU – Lost to follow-up; TB – tuberculosis.

#### **S5 Fig. Cohort prevalence of *M. tb.* resistance to key drugs at treatment initiation.**

The proportion of the cohort with primary resistance to each drug is plotted, as described by *M. tuberculosis* whole genomic sequencing data from Moldova [30,35]. All those observations with rifampicin susceptibility were excluded, as per S3 Fig. \*There was no resistance data for pretomanid; resistance was assumed to be at the same level as for delamanid.

#### **S6 Fig. WHO-based definitions for End of Treatment Outcomes.**

Schematic showing the definitions for end of treatment outcomes used by the WHO (A), and this model (B). The constituents of each of the major end of treatment outcome categories are shown, as applied to all RR-TB including MDR-TB and XDR-TB. Differences between the WHO definitions and those used in this model are highlighted by the gray hashed boxes. The WHO definitions are not necessarily mutually exclusive; we assumed that the classification takes place according to the tree structure in (A),

and implemented the aligned structure in (B) for tractability given the model mechanisms. For example, an individual who failed treatment and then died would be recorded as a death, because the branch involving death is closer to the root of the tree.

**S7 Fig. Incremental cost-effectiveness plane for the leading 6-month BPaLM strategy vs. the leading SOC strategy.**

The incremental cost-effectiveness plane compares the incremental discounted total QALYs and incremental discounted total costs for Strategy (1) as compared to a reference of Strategy (7). Each light pink point represents one iteration of the second-order Monte Carlo simulation, itself an average of 10,000 individual patient simulations. The purple diamond is the mean of the 1,000 second-order Monte Carlo simulations, corresponding to the point estimates in Table 3. The blue dot represents the standard of care (Strategy (7)), which is the reference point. BPaL – bedaquiline, pretomanid, linezolid; BPaLC – bedaquiline, pretomanid, linezolid, clofazimine; BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; FQ-R – fluoroquinolone-resistant; FQ-S – fluoroquinolone-susceptible; Mfx – moxifloxacin; QALY – quality-adjusted life year; USD – United States dollars; WTP – willingness-to-pay

**S8 Fig. Sensitivity analyses varying relative effectiveness of BPaLM and cohort prevalence of fluoroquinolone resistance, outcome of Life Years.**




One-way sensitivity analyses testing the effect of key model parameter assumptions, in terms of their effect on the incremental Life Years experienced under the Strategy (1) (6 months BPaLM, DST upfront, repeat DST every 4 months, BPaLC if Mfx stopped) as compared to Strategy (7) (standard of care 9-18 month regimens based on results of upfront DST, repeat DST every 4 months). We chose to compare these two strategies as they were the best-performing BPaLM-based and standard of care-based strategies, respectively. Each of the parameters is varied deterministically in the respective sensitivity analysis, with all other model parameters drawn as in the probabilistic sensitivity analysis. In the left column, the HRR







of cure for the BPaLM regimen compared to the standard of care is varied. In the right column, we vary the starting prevalence of fluoroquinolone resistance in the cohort. Each of 1,000 model runs is shown in each plot, itself an average of 10,000 individual patient simulations. The red line shows the trend as represented by regression of the y-axis variable on the x-axis variable, using a generalized additive model with cubic spline to obtain a restricted maximum likelihood within ggplot2 [58]. The vertical dashed lines mark the base case assumption for the mean of each of these model parameters. FQR – Fluoroquinolone Resistance; HRR – Hazard Rate Ratio; LY –Life Year; RR-TB – Rifampicin-resistant tuberculosis

**S9 Fig. Validating modeled End of Treatment outcomes against data reported to WHO.**


The proportions recorded for each EOT outcome are shown for WHO RR-TB data 2010–2019 for Moldova (left of the vertical dashed line) and the modeled cohort outcomes (right of the vertical dashed line), where we assume that all EOT outcome categories are mutually exclusive, and that death during treatment or LTFU take precedence over a preceding treatment failure. Standard of care refers to modelled Strategy 7, and 6 months BPaLM refers to modelled Strategy 1. The number of observations per year in the WHO TB outcomes data for all MDR/RR-TB is in the range (559, 996).

BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; EOT – End Of Treatment; LTFU – Lost to Follow Up; RR-TB – Rifampicin-resistant tuberculosis; WHO – World Health Organization






Lifetime cumulative incidence of Grade 4-5 SAEs (per patient)



Strategy  
(1): 6 months BPaLM  
(7): Standard of Care

Difference in the mean duration with TB disease resistant to each drug (months)



Counting time with resistance among:

- Entire cohort
- Only those with higher transmission risk (i.e., active TB no longer receiving treatment)

BPaLM INCREASES time with TB disease resistant to drug, compared to SOC

BPaLM DECREASES time with TB disease resistant to drug, compared to SOC

Drug

